An in-depth look at this medical topic, providing essential context for patients and caregivers.
General Medical Overview
Acute myeloid leukemia (AML): A condition categorized under Hematology (Leukemia & Lymphoma).
Acute myeloid leukemia (AML) is an aggressive hematological malignancy characterized by the rapid proliferation of immature myeloid blast cells in the bone marrow, peripheral blood, and occasionally other tissues. It is the most common acute leukemia in adults, with a median age at diagnosis of 68 years. The 2022 WHO classification recognizes over 20 distinct AML subtypes based on genetic alterations, each with different prognoses and treatment implications. The disease can arise de novo or evolve from myelodysplastic syndromes (MDS) or prior chemotherapy/radiation.
Typical Treatment Roadmap
Detection
Symptoms and initial checkup.
Diagnosis
Biopsy and clinical imaging.
Treatment
Therapy (Surgery, Chemo, etc.)
Monitoring
Follow-up and recovery.
Clinical Manifestation (Main Symptoms)
Clinically, the initial presentation of Acute myeloid leukemia (AML) often manifests with Fatigue, Fever, Night Sweats, Bruising and Swollen Nodes.
Advanced Stage Signs (Warning)
Easy bruising and petechiae (from thrombocytopenia), recurring infections and persistent fevers (from neutropenia), severe fatigue and dyspnea (from anemia), gum hypertrophy and skin infiltration (monocytic subtypes), disseminated intravascular coagulation (DIC, especially in APL), and leukostasis in hyperleukocytic presentations.
Diagnostic Procedures
Complete blood count showing cytopenias with circulating blasts (≥20% blasts in marrow defines AML), bone marrow aspirate and biopsy with morphology, flow cytometry for immunophenotyping, cytogenetics (karyotype), and molecular testing (FLT3, NPM1, CEBPA, IDH1/2, TP53, RUNX1 mutations). Risk stratification (ELN 2022 guidelines) guides treatment intensity.
Medical Risk Factors
Advanced age (median diagnosis age 68), prior chemotherapy with alkylating agents or topoisomerase II inhibitors (therapy-related AML), myelodysplastic syndromes (MDS progression), benzene exposure, high-dose radiation, Down syndrome, Fanconi anemia, and smoking.
Therapeutic Approach
Induction chemotherapy with '7+3' (cytarabine 7 days + daunorubicin 3 days) for fit patients. Consolidation with high-dose cytarabine (HiDAC) or allogeneic stem cell transplant for intermediate/adverse risk. FLT3 inhibitors (midostaurin, gilteritinib) for FLT3-mutated AML. IDH1/2 inhibitors (ivosidenib, enasidenib) for IDH-mutated AML. Venetoclax plus azacitidine for older/unfit patients — a practice-changing regimen. Gemtuzumab ozogamicin for CD33-positive disease.
Medical Breakthroughs & Hope
AML treatment has been revolutionized by molecular classification and targeted therapies. The combination of venetoclax plus azacitidine has transformed outcomes for older patients who previously had few effective options. FLT3 and IDH inhibitors provide precise treatment targeting the specific genetic drivers of each patient's leukemia.
Prognosis & Efficacy29%
The 5-year survival rate for AML varies dramatically by age and molecular subtype: approximately 40-50% for patients under 60 with favorable genetics, but only 5-15% for patients over 65 with adverse-risk disease. Favorable-risk AML (NPM1-mutated without FLT3-ITD, core binding factor AML) has 5-year survival exceeding 60%.
Myth vs. Clinical Reality
Myth / Fiction
Leukemia only affects children.
Fact / Reality
AML primarily affects adults, with a median age of 68. While childhood leukemias exist, AML is predominantly an adult disease with increasing incidence with age.
Myth / Fiction
Leukemia is always fatal.
Fact / Reality
With modern targeted therapies and molecular classification, many AML patients achieve long-term remission or cure. Outcomes vary by subtype, but even for adverse-risk disease, new treatments are improving survival.
Frequently Asked Questions (FAQ)
Is AML the same as CML?
No. AML is an acute, rapidly progressive leukemia requiring immediate treatment. CML is a chronic leukemia with a slow course, managed with oral targeted pills (TKIs). They have completely different biology and treatment.
What determines if I need a transplant?
This depends on molecular risk stratification. Favorable-risk AML may be cured with chemotherapy alone. Intermediate and adverse-risk patients often benefit from allogeneic stem cell transplant in first remission.
Can AML be caused by previous cancer treatment?
Yes. Therapy-related AML (t-AML) can occur years after chemotherapy or radiation for another cancer, accounting for approximately 10-20% of AML cases. It generally has adverse-risk genetics.
What is the difference between remission and cure?
Complete remission means no detectable leukemia by standard tests. To be considered 'cured,' patients typically need to remain in remission for 3-5+ years. Measurable residual disease (MRD) testing helps assess depth of response.
How has treatment changed for elderly patients?
Venetoclax combined with azacitidine has dramatically improved outcomes for older/unfit patients, achieving complete remission in 60-70% — a major advance over previous 'best supportive care' approaches.